MCID: LYM027
MIFTS: 56

Lymphopenia

Categories: Immune diseases, Blood diseases

Aliases & Classifications for Lymphopenia

MalaCards integrated aliases for Lymphopenia:

Name: Lymphopenia 12 28 51 41 14 69
Lymphocytopenia 12 59

Classifications:



External Ids:

Disease Ontology 12 DOID:614
ICD10 32 D72.810
ICD9CM 34 288.51
MeSH 41 D008231
SNOMED-CT 64 48813009
UMLS 69 C0024312

Summaries for Lymphopenia

PubMed Health : 59
About lymphocytopenia: Lymphocytopenia (LIM-fo-si-to-PE-ne-ah) is a disorder in which your blood doesn’t have enough white blood cells called lymphocytes (LIM-fo-sites).These cells are made in the bone marrow along with other kinds of blood cells. Lymphocytes help protect your body from infection. Low numbers of lymphocytes can raise your risk of infection.Lymphocytopenia also is called lymphopenia.

MalaCards based summary : Lymphopenia, also known as lymphocytopenia, is related to alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity and thymic dysplasia. An important gene associated with Lymphopenia is RAG1 (Recombination Activating 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Rho(D) Immune Globulin and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and bone, and related phenotypes are endocrine/exocrine gland and hematopoietic system

Disease Ontology : 12 A leukopenia that is the condition of having an abnormally low level of lymphocytes in the blood.

Wikipedia : 72 Lymphocytopenia, or lymphopenia, is the condition of having an abnormally low level of lymphocytes in... more...

Related Diseases for Lymphopenia

Diseases related to Lymphopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 254)
# Related Disease Score Top Affiliating Genes
1 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 33.4 FOXP3 IFNG RAG1
2 thymic dysplasia 29.8 FOXP3 IL2RG IL7
3 autoimmune enteropathy 29.5 FOXP3 IL2RA
4 pancreas adenocarcinoma 29.2 FOXP3 IFNG IL7
5 severe combined immunodeficiency 29.1 IL2 IL2RG IL7 IL7R RAG1
6 cryptococcosis 29.0 IFNG SELL UNC119
7 b-cell expansion with nfkb and t-cell anergy 29.0 FASLG IL2 IL2RA SELL
8 thyroiditis 28.9 FASLG IFNG IL2
9 adult t-cell leukemia 28.8 FAS FOXP3 IL2 IL2RA
10 cytomegalovirus infection 28.8 FAS IFNG IL2RA RAG1
11 combined immunodeficiency, x-linked 28.6 CD3G IL2 IL2RA IL2RG IL7 IL7R
12 pulmonary sarcoidosis 28.6 IFNG IL2 IL2RA
13 conjunctivitis 28.6 FOXP3 IFNG IL2
14 erythema multiforme 28.6 FASLG IFNG IL2
15 graft-versus-host disease 28.5 FAS FASLG IFNG IL2
16 visceral leishmaniasis 28.4 FOXP3 IFNG IL2
17 autoimmune disease 28.4 FAS FOXP3 IFNG IL2 IL2RA
18 systemic lupus erythematosus 28.4 FAS FASLG FOXP3 IFNG IL2 IL2RA
19 acute graft versus host disease 28.2 FASLG IFNG IL2 IL2RA
20 omenn syndrome 28.2 FOXP3 IFNG IL2RG IL7R RAG1
21 alopecia areata 28.2 FASLG IFNG IL2 IL2RA
22 hashimoto thyroiditis 27.9 FAS FASLG IFNG IL2 IL2RA
23 renal cell carcinoma, nonpapillary 27.9 FAS FASLG IFNG IL2 IL2RA
24 multiple sclerosis 27.6 FASLG FOXP3 IFNG IL2 IL2RA IL7
25 malaria 27.4 CD55 FASLG FOXP3 IFNG IL2
26 common variable immunodeficiency 27.1 FAS FOXP3 IFNG IL2 IL2RA LCK
27 immunodeficiency 13 11.8
28 idiopathic cd4-positive t-lymphocytopenia 11.5
29 immunodeficiency, x-linked, with magnesium defect, epstein-barr virus infection, and neoplasia 10.9
30 immunodeficiency 50 10.9
31 immunodeficiency 14 10.9
32 immunodeficiency 17 10.9
33 sideroblastic anemia with b-cell immunodeficiency, periodic fevers, and developmental delay 10.9
34 short stature, microcephaly, and endocrine dysfunction 10.9
35 immunodeficiency 52 10.9
36 aplasia cutis congenita with intestinal lymphangiectasia 10.8
37 schimke immunoosseous dysplasia 10.8
38 reticular dysgenesis 10.8
39 neutropenia, severe congenital, 4, autosomal recessive 10.8
40 immunodeficiency 8 10.8
41 immunodeficiency 22 10.8
42 immunodeficiency 37 10.8
43 immunodeficiency 40 10.8
44 immunodeficiency 49 10.8
45 combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia 10.8
46 caplan's syndrome 10.3 FAS FOXP3
47 lymphoproliferative syndrome 2 10.3 IL2RA MAGT1 PIK3CD
48 type ii mixed cryoglobulinemia 10.3 FAS FASLG
49 lymphocytic gastritis 10.3 FAS FASLG
50 balo concentric sclerosis 10.2 IL2RA SELL

Graphical network of the top 20 diseases related to Lymphopenia:



Diseases related to Lymphopenia

Symptoms & Phenotypes for Lymphopenia

MGI Mouse Phenotypes related to Lymphopenia:

43 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.36 SELL FAS G6PC3 IFNG FASLG CD3G
2 hematopoietic system MP:0005397 10.36 SELL CD59 FAS G6PC3 IFNG FASLG
3 cellular MP:0005384 10.27 RAG1 SELL CD59 FOXP3 FAS IFNG
4 immune system MP:0005387 10.27 SELL FOXP3 FAS G6PC3 IFNG FASLG
5 homeostasis/metabolism MP:0005376 10.18 RAG1 SELL CD59 FOXP3 FAS G6PC3
6 cardiovascular system MP:0005385 10.16 RAG1 SELL UNC119 FOXP3 FAS FASLG
7 digestive/alimentary MP:0005381 10.13 RAG1 FOXP3 FAS IFNG FASLG IL2
8 liver/biliary system MP:0005370 9.92 RAG1 SELL UNC119 FOXP3 FAS FASLG
9 neoplasm MP:0002006 9.86 RAG1 SELL FAS IFNG FASLG IL7R
10 normal MP:0002873 9.76 RAG1 FOXP3 FAS FASLG IL7R MAGT1
11 respiratory system MP:0005388 9.61 SELL FOXP3 FAS IFNG FASLG IL2
12 vision/eye MP:0005391 9.23 RAG1 UNC119 FOXP3 FAS FASLG IL2

Drugs & Therapeutics for Lymphopenia

PubMedHealth treatment related to Lymphopenia: 59

If you have mild lymphocytopenia with no underlying cause, you may not need treatment. The disorder may improve on its own.If you have unusual infections, repeat infections, and/or infections that won't go away due to lymphocytopenia, you'll need treatment for the infections.If you have a disease or condition that's causing lymphocytopenia, your doctor will prescribe treatment for that illness. Treating the underlying problem will help treat the lymphocytopenia.

Drugs for Lymphopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Rho(D) Immune Globulin Phase 4,Phase 3
2 gamma-Globulins Phase 4,Phase 3
3 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
4 Immunoglobulins, Intravenous Phase 4,Phase 3
5 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
6
Zinc Approved, Investigational Phase 3 7440-66-6 32051 23994
7
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
8
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
9
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
10 Gastrointestinal Agents Phase 3,Phase 1
11 Peripheral Nervous System Agents Phase 3,Phase 1
12 Antiemetics Phase 3,Phase 1
13 Protective Agents Phase 3
14 Neurotransmitter Agents Phase 3,Phase 2
15 Micronutrients Phase 3
16 Trace Elements Phase 3
17 Dopamine Agents Phase 3
18 Dopamine Antagonists Phase 3
19 Dopamine D2 Receptor Antagonists Phase 3
20 Antioxidants Phase 3
21 Autonomic Agents Phase 3
22 glutamine Nutraceutical Phase 3
23 Whey Protein Nutraceutical Phase 3
24
Melphalan Approved Phase 2,Phase 1 148-82-3 460612 4053
25
Gemcitabine Approved Phase 2 95058-81-4 60750
26
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
27
Busulfan Approved, Investigational Phase 1, Phase 2 55-98-1 2478
28
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
29
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
30
Dacarbazine Approved, Investigational Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
31
Temozolomide Approved, Investigational Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
32 Thiotepa Approved, Investigational Phase 2,Phase 1 52-24-4 5453
33
Lenalidomide Approved Phase 2 191732-72-6 216326
34
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
35
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
36
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
37
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
38
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
39
Vidarabine Approved, Investigational Phase 2,Phase 1 24356-66-9 21704 32326
40
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
41
alemtuzumab Approved, Investigational Phase 2 216503-57-0
42
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
43
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
44
Pembrolizumab Approved Phase 2 1374853-91-4
45
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
46
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
47
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
48
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
49
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
50
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903

Interventional clinical trials:

(show top 50) (show all 112)

# Name Status NCT ID Phase Drugs
1 A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Completed NCT01289847 Phase 4
2 Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis Completed NCT01321164 Phase 3 Fumaric acid esters
3 Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. Completed NCT00278954 Phase 3
4 Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients Completed NCT00220766 Phase 3 Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Dextrose, 5% in Water
5 The CRISIS Prevention Study Terminated NCT00395161 Phase 3 Metoclopramide;Zinc;Selenium
6 GVAX in Advanced Prostate Cancer Patients Made Lymphopenic Unknown status NCT00122005 Phase 1, Phase 2
7 Gene Therapy for WAS Unknown status NCT01347346 Phase 1, Phase 2
8 Gene Therapy for Wiskott-Aldrich Syndrome (WAS) Unknown status NCT01347242 Phase 1, Phase 2
9 Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients Completed NCT01368107 Phase 2 placebo;interleukin 7;interleukin 7;interleukin 7
10 Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer Completed NCT00771810 Phase 2 TXA127;TXA127;Placebo
11 A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation Completed NCT00405327 Phase 2
12 Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy Completed NCT00815321 Phase 2
13 [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Completed NCT01717391 Phase 2 fluorothymidine F 18
14 Cetuximab and Lenalidomide in Head and Neck Completed NCT01133665 Phase 2 Cetuximab and Lenalidomide
15 Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis Completed NCT02780167 Phase 2 PF-04965842;PF-04965842;PF-04965842;PF-04965842;Placebo
16 Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS) Completed NCT00885833 Phase 1, Phase 2 Fludarabine, Busulfan, Thymoglobulin
17 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
18 Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide Recruiting NCT03139851 Phase 2 Cyclophosphamide 50mg;Pembrolizumab 100 MG in 4 ML Injection
19 EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer Recruiting NCT02001272 Phase 2 Paclitaxel + Carboplatin every 3 weeks;Carboplatin monotherapy every 3 weeks;Weekly Paclitaxel and Carboplatin
20 Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Recruiting NCT02179086 Phase 2 temozolomide
21 Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant Recruiting NCT03330795 Phase 1, Phase 2
22 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Recruiting NCT03333486 Phase 2 Cyclophosphamide;Fludarabine Phosphate
23 A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients Recruiting NCT03019809 Phase 2
24 Gene Therapy for WAS Follow-up Recruiting NCT02333760 Phase 1, Phase 2
25 Immune Disorder HSCT Protocol Recruiting NCT01821781 Phase 2 Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
26 Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata Active, not recruiting NCT02974868 Phase 2 PF-06651600;PF-06700841;Placebo
27 A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients Active, not recruiting NCT02640807 Phase 2 Interleukin-7;Placebo
28 Pyridostigmine as Immunomodulator in People Living With HIV Active, not recruiting NCT03312244 Phase 2 Pyridostigmine Bromide;Placebo
29 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
30 Gene Therapy for Wiskott-Aldrich Syndrome Active, not recruiting NCT01515462 Phase 2
31 Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome Active, not recruiting NCT01410825 Phase 1, Phase 2
32 Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients Active, not recruiting NCT00909363 Phase 2 Promacta (eltrombopag);Eltrombopag/promacta
33 Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases Enrolling by invitation NCT01852370 Phase 1, Phase 2
34 Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH) Not yet recruiting NCT03338998 Phase 2 BAF312;Placebo
35 Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE) Terminated NCT00839436 Phase 1, Phase 2 CYT107
36 FLT PET Imaging for Cervical Cancer Terminated NCT01075412 Phase 2 [F18]Fluorothymidine
37 A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients Terminated NCT00849875 Phase 2 Dacarbazine
38 Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer Terminated NCT01220128 Phase 2 Placebo;Aromatase inhibitor;5-Fluorouracil;Carboplatin AUC;Cyclophosphamide;Docetaxel;Doxorubicin;Epirubicin;Paclitaxel;Trastuzumab
39 Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells Terminated NCT02512679 Phase 2 Cyclophosphamide Dose Level 1;Cyclophosphamide Dose Level 2;Cyclophosphamide Dose Level 3;Cyclophosphamide Dose Level 4
40 Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer Completed NCT00693095 Phase 1
41 Safety Study of IL-7 in HIV-infected Patients (Inspire) Completed NCT00477321 Phase 1 CYT 107
42 Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma Completed NCT00091143 Phase 1 fludarabine phosphate
43 A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects Completed NCT02211469 Phase 1 BMS-986104;Placebo
44 A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. Completed NCT01466322 Phase 1 GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
45 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
46 Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant Completed NCT00684008 Phase 1 CYT107 - Recombinant glycosylated human interleukin 7.;rhIL-7 (CYT107)
47 Study of Dasatinib (BMS-354825) in Patients With Solid Tumors Completed NCT00339144 Phase 1 Dasatinib;Dasatinib;Dasatinib
48 Interleukin-2 Treatment for Wiskott-Aldrich Syndrome Completed NCT00774358 Phase 1 Interleukin-2
49 Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome Completed NCT00160355 Phase 1 Fludarabine, Melphalan, Thiotepa
50 EGFRvIII CAR T Cells for Newly-Diagnosed GBM Recruiting NCT02664363 Phase 1

Search NIH Clinical Center for Lymphopenia

Cochrane evidence based reviews: lymphopenia

Genetic Tests for Lymphopenia

Genetic tests related to Lymphopenia:

# Genetic test Affiliating Genes
1 Lymphopenia 28

Anatomical Context for Lymphopenia

MalaCards organs/tissues related to Lymphopenia:

38
T Cells, Bone Marrow, Bone, Breast, B Cells, Lung, Liver

Publications for Lymphopenia

Articles related to Lymphopenia:

(show top 50) (show all 602)
# Title Authors Year
1
Erratum: Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod. ( 29417951 )
2018
2
A Severe Neonatal Lymphopenia Associated With Administration of Azathioprine to the Mother in a Context of Crohn's Disease. ( 28961694 )
2018
3
The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. ( 28963724 )
2018
4
Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod. ( 29296636 )
2018
5
Lymphopenia and fumaric acid esters for psoriasis: a retrospective case series prompted by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommendations. ( 29027699 )
2018
6
Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. ( 29143923 )
2018
7
Pre-treatment lymphopenia and indication of tumor-induced systemic immunosuppression in medulloblastoma. ( 29143922 )
2018
8
Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. ( 29248170 )
2017
9
Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial. ( 28736763 )
2017
10
What Does Screening Newborns for T-Cell Lymphopenia Find? ( 28888255 )
2017
11
PD-1 Controls Tonic Signaling and Lymphopenia-Induced Proliferation of T Lymphocytes. ( 29075267 )
2017
12
Radiation-related lymphopenia is associated with spleen irradiation dose during radiotherapy in patients with hepatocellular carcinoma. ( 28558844 )
2017
13
Idiopathic T cell lymphopenia identified in New York State Newborn Screening. ( 28694137 )
2017
14
Large Deletion of MAGT1 Gene in a Patient with Classic Kaposi Sarcoma, CD4 Lymphopenia, and EBV Infection. ( 27770395 )
2017
15
Lymphopenia and CD4+/CD8+ Cell Reduction under Fumaric Acid Esters. ( 28954274 )
2017
16
Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia. ( 28576902 )
2017
17
First Report of CD4 Lymphopenia and Defective Neutrophil Functions in a Patient with Amebiasis Associated with CMV Reactivation and Severe Bacterial and Fungal Infections. ( 28243230 )
2017
18
New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth. ( 28695300 )
2017
19
The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients. ( 28392551 )
2017
20
Systemic inflammatory response syndrome-related lymphopenia is associated with adenosine A1 receptor dysfunction. ( 28495790 )
2017
21
Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap? ( 28543950 )
2017
22
Depletion-Resistant CD4 T Cells Enhance Thymopoiesis During Lymphopenia. ( 28397358 )
2017
23
Profound T-cell lymphopenia associated with prenatal exposure to purine antagonists detected by TREC newborn screening. ( 28065337 )
2017
24
Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation. ( 29205270 )
2017
25
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated I+I^ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma. ( 28668896 )
2017
26
Predominance of CD4+ T Cells in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma and Identification of a Subset of Patients With Peripheral B-Cell Lymphopenia. ( 28575178 )
2017
27
Susceptibility to Cryptococcal Meningoencephalitis Associated With Idiopathic CD4(+) Lymphopenia and Secondary Germline or Acquired Defects. ( 28638843 )
2017
28
T-Cell Lymphopenia Detected by Newborn Screening in Two Siblings with an Xq13.1 Duplication. ( 28770187 )
2017
29
Cryptococcal meningitis in apparently immunocompetent patients: association with idiopathic CD4+ lymphopenia. ( 29223998 )
2017
30
Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma. ( 29022484 )
2017
31
Intestinal microbiota link lymphopenia to murine autoimmunity via PD-1(+)CXCR5(-/dim) B-helper T cell induction. ( 28443628 )
2017
32
Dysplasia of Granulocytes in a Patient with HPV Disease, Recurrent Infections, and B Lymphopenia: A Novel Variant of WHIM Syndrome? ( 28512628 )
2017
33
Dosimetric Predictors of Treatment-related Lymphopenia induced by Palliative Radiotherapy: Predictive Ability of Dose-volume Parameters based on Body Surface Contour. ( 28740459 )
2017
34
T-cell lymphopenia in 22q11.2 deletion syndrome: Relationship to cardiac disease. ( 28964704 )
2017
35
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpointA blockers (PD-1/PD-L1 inhibitors). ( 28826073 )
2017
36
Lymphopenia at 4 Days Postoperatively Is the Most Significant Laboratory Marker for Early Detection of Surgical Site Infection Following Posterior Lumbar Instrumentation Surgery. ( 27994779 )
2016
37
A Clinical Approach to a Child with Hypoalbuminemia and Lymphopenia. ( 27026169 )
2016
38
Risk Factors and Clinical Significance of Lymphopenia in Survivors of the Fontan Procedure for Single-Ventricle Congenital Cardiac Disease. ( 26897303 )
2016
39
PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter? ( 27343070 )
2016
40
Lymphopenia and Elevated Blood C-Reactive Protein Levels at Four Days Postoperatively Are Useful Markers for Early Detection of Surgical Site Infection Following Posterior Lumbar Instrumentation Surgery. ( 27114760 )
2016
41
The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. ( 27214202 )
2016
42
FTY720-Induced Lymphopenia does not Aggravate Mortality in a Murine Model of Polymicrobial Abdominal Sepsis. ( 27559700 )
2016
43
Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. ( 26725885 )
2016
44
Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer. ( 27354621 )
2016
45
CD4 T Helper Cells Instruct Lymphopenia-Induced Memory-Like CD8 T Cells for Control of Acute LCMV Infection. ( 28066432 )
2016
46
Patterns of Radiation-Associated Lymphopenia in Children with Cancer. ( 26745229 )
2016
47
Worsening of Lymphopenia during Apremilast Treatment. ( 27920684 )
2016
48
IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopenia. ( 27158441 )
2016
49
Idiopathic CD4 Lymphopenia: Severe CD4 Lymphopenia in the Absence of Human Immunodeficiency Virus Infection. ( 28471626 )
2016
50
Apoptosis-induced lymphopenia in sepsis and other severe injuries. ( 27812767 )
2016

Variations for Lymphopenia

Expression for Lymphopenia

Search GEO for disease gene expression data for Lymphopenia.

Pathways for Lymphopenia

Pathways related to Lymphopenia according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 CD3G CD55 CD59 FASLG IFNG IL2
2
Show member pathways
13.67 CD3G FAS FASLG IFNG IL2 IL2RA
3
Show member pathways
13.46 CD3G FAS FASLG IL2 IL2RA IL2RG
4
Show member pathways
13.41 FASLG IFNG IL2 IL2RA IL2RG IL7
5
Show member pathways
13.3 FAS FASLG IL2 IL2RA IL2RG IL7
6
Show member pathways
12.99 FAS FASLG G6PC3 IL2 IL2RA IL2RG
7
Show member pathways
12.88 CD3G CD55 FAS FASLG FOXP3 IFNG
8
Show member pathways
12.83 IL2 IL2RA IL2RG IL7 IL7R PIK3CD
9 12.83 FAS FASLG IFNG IL2 IL2RA IL2RG
10
Show member pathways
12.82 CD3G FAS FASLG IFNG IL2 IL2RA
11
Show member pathways
12.7 CD3G IFNG IL2 IL2RA LCK PIK3CD
12
Show member pathways
12.66 CD3G FOXP3 IFNG IL2 IL2RA IL2RG
13
Show member pathways
12.62 CD3G FAS FASLG IFNG IL2 PIK3CD
14
Show member pathways
12.6 FAS FASLG IFNG IL2 LCK PIK3CD
15 12.55 FAS FASLG FOXP3 IFNG IL2 IL2RA
16
Show member pathways
12.51 CD3G FAS IFNG IL2 LCK PIK3CD
17 12.49 CD3G IL2 IL2RA IL2RG LCK PIK3CD
18
Show member pathways
12.45 CD3G IL2 IL2RA IL2RG LCK
19
Show member pathways
12.33 IFNG IL2 IL2RA IL2RG IL7 IL7R
20
Show member pathways
12.24 IL2 IL2RA IL2RG LCK PIK3CD
21
Show member pathways
12.18 FASLG G6PC3 IL7R PIK3CD RAG1
22
Show member pathways
12.16 IFNG IL2 IL2RA IL2RG LCK
23
Show member pathways
12.14 CD3G IL2 LCK PIK3CD
24
Show member pathways
12.05 IL2 IL2RA IL2RG LCK PIK3CD
25 11.94 CD3G CD55 CD59 IL2RA IL7 IL7R
26 11.89 IFNG IL2 IL2RA IL7R
27 11.87 IFNG IL2 IL2RA IL7 IL7R
28 11.83 IFNG IL2 IL7R SELL
29
Show member pathways
11.83 FASLG FOXP3 IFNG IL2 IL2RA
30 11.76 CD59 IFNG IL2 IL2RA IL7 IL7R
31 11.73 FAS FASLG PIK3CD
32 11.65 FAS FASLG IFNG IL2
33
Show member pathways
11.62 FASLG FOXP3 IL2 IL2RA IL2RG LCK
34
Show member pathways
11.57 IL2RA IL2RG IL7 IL7R
35 11.56 FOXP3 IFNG IL2 IL2RA IL2RG
36
Show member pathways
11.55 CD3G FASLG IFNG IL2 IL2RA IL2RG
37
Show member pathways
11.52 CD3G FASLG IFNG IL2 IL2RA IL2RG
38 11.47 IL2RG IL7R LCK RAG1
39 11.4 FAS FASLG IFNG
40 11.34 CD3G IFNG IL2 IL2RA
41 11.33 IFNG IL2 IL7
42 11.33 IL2RG IL7 IL7R RAG1
43 11.28 IFNG IL2 IL2RA IL2RG LCK
44
Show member pathways
10.72 FAS FASLG FOXP3 IFNG IL2 IL2RA

GO Terms for Lymphopenia

Cellular components related to Lymphopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.87 CD3G CD55 FAS FASLG IL2RG MAGT1
2 membrane raft GO:0045121 9.46 CD55 FAS FASLG LCK
3 cell surface GO:0009986 9.43 CD55 CD59 FAS FASLG IL2RA SELL
4 external side of plasma membrane GO:0009897 9.02 FASLG IL2RA IL2RG IL7R SELL
5 plasma membrane GO:0005886 10.03 CD3G CD55 CD59 FAS FASLG IL2RA

Biological processes related to Lymphopenia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.99 CD3G CD55 IL2 IL2RA PIK3CD
2 cell surface receptor signaling pathway GO:0007166 9.85 CD3G CD59 IFNG IL2RA IL7R
3 T cell receptor signaling pathway GO:0050852 9.83 CD3G FOXP3 LCK PIK3CD
4 adaptive immune response GO:0002250 9.8 CD3G IFNG IL2 PIK3CD RAG1
5 negative regulation of inflammatory response GO:0050728 9.79 FOXP3 IL2 IL2RA
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.76 FAS FASLG LCK
7 T cell activation GO:0042110 9.72 CD3G FOXP3 PIK3CD
8 extrinsic apoptotic signaling pathway GO:0097191 9.69 FAS FASLG IFNG
9 interleukin-7-mediated signaling pathway GO:0038111 9.67 IL2RG IL7 IL7R LCK
10 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.62 FAS FASLG
11 negative regulation of immune response GO:0050777 9.62 FOXP3 IL2RA
12 T cell differentiation GO:0030217 9.62 IL2 IL7R LCK PIK3CD
13 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.61 FAS FASLG
14 T cell homeostasis GO:0043029 9.61 FOXP3 IL2RA RAG1
15 negative regulation of interleukin-17 production GO:0032700 9.58 FOXP3 IFNG
16 positive regulation of regulatory T cell differentiation GO:0045591 9.57 FOXP3 IL2
17 necroptotic signaling pathway GO:0097527 9.56 FAS FASLG
18 negative regulation of T-helper 17 cell differentiation GO:2000320 9.54 FOXP3 IL2
19 interleukin-2-mediated signaling pathway GO:0038110 9.49 IL2RA IL2RG
20 regulation of T cell homeostatic proliferation GO:0046013 9.48 IL2 IL2RA
21 positive regulation of T cell differentiation GO:0045582 9.46 IL2 IL2RA IL7 RAG1
22 negative regulation of lymphocyte proliferation GO:0050672 9.43 FOXP3 IL2 IL2RA
23 immune response GO:0006955 9.28 FAS FASLG IFNG IL2 IL2RA IL2RG
24 regulation of regulatory T cell differentiation GO:0045589 9.26 FOXP3 IFNG IL2 IL2RA
25 positive regulation of cell proliferation GO:0008284 10 FASLG IFNG IL2 IL7 IL7R

Molecular functions related to Lymphopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.67 FASLG IFNG IL2 IL7
2 T cell receptor binding GO:0042608 9.32 CD3G LCK
3 glycosphingolipid binding GO:0043208 9.26 IL2 SELL
4 interleukin-2 receptor activity GO:0004911 9.16 IL2RA IL2RG
5 interleukin-2 binding GO:0019976 8.96 IL2RA IL2RG
6 interleukin-7 receptor activity GO:0004917 8.62 IL2RG IL7R
7 protein binding GO:0005515 10.31 CD55 CD59 FAS FASLG FOXP3 IFNG

Sources for Lymphopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....